Pricing Log in Create free account
Saturday 17 October 2026 Export CNSY’s income statement to Excel — free account

Cerenome, Inc.

CNSY Healthcare Biotechnology

Cerenome, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5.2 million, down 10.5% from fiscal 2024. In the quarter to June 2026, revenue fell 70.4%, EPS fell 362.0% and free cash flow fell 31.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.70 0.18 −9.57%
Market cap
$14.3M
P/E
0.0×
Fwd P/E
−1.4×
Dividend yield
—
F-score
3/9
Altman Z
−44.87
Beneish M
−3.46
Dividend safety
n/a
Overview Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.01
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy 1 — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 14.27
Revenue 4.20
Net Income (26.09)
Free Cash Flow (23.55)
Net Debt (2.37)
Current Ratio 1.37
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (1.40) (negative: loss-making)
P/S ratio 2.79
P/B ratio 2.15
Past 5Y EPS Growth —
This Y EPS Growth 34.41% (at or above 15%: strong)
Next Y EPS Growth 45.85% (at or above 15%: strong)
Next Y revenue growth (28.64%) (below 0%: weak)
Next 5Y EPS Growth 80.97% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 3.3×, against a ten-year median of 2.5×; over the ten years it ranged from −7.2× in 2023 to 2,235,227× in 2016.
P/S against its own 10 years 50.94%
10-year low 10-year high
P/B against its own 10 years 45.72%
10-year low 10-year high
EV/Sales against its own 10 years 46.37%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 9 4 13 2
Receivables — 1 0 2
Inventory — — — 6
Other 1 1 2 1
10 5 15 12
2023 2024 2025 Q'26
Payables 7 11 6 8
ST’ Debt 4 3 1 —
Other — 1 6 1
11 16 12 9

Compound Annual Growth %

10y 5y 3y
Sales 0.51% (5.72%) 185.50%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (10.57%) 5.68% (14.73%)

Revenue $m

Mar Jun Sep Dec Year
’26 1 0 — — —
’25 1 1 1 1 5
’24 2 1 1 1 6
’23 1 2 1 1 5
’22 — — 0 0 0
’20 0 0 — — 0
’19 1 0 5 1 7
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (6) (7) — — —
’25 (6) (6) (3) (6) (21)
’24 (5) (1) (4) (1) (11)
’23 (6) (3) (2) (2) (13)
’22 (4) (3) (4) (2) (13)
’21 (3) (2) (2) (3) (10)
’20 (2) (1) (2) (3) (8)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (7) (8) — — —
’25 (6) (6) (3) (6) (21)
’24 (5) (2) (4) (1) (11)
’23 (6) (3) (2) (2) (13)
’22 (4) (3) (4) (2) (13)
’21 (3) (2) (2) (3) (10)
’20 (2) (1) (2) (3) (9)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (1.05) (1.31) — — —
’25 (29.75) (0.25) (1.00) 0.00 (7.25)
’24 (18.75) (6.84) (9.25) (16.75) (42.13)
’23 (51.78) (14.75) (25.00) (17.50) (106.00)
’22 (71.73) (88.98) (71.34) (899.10) (289.64)
’21 (123.31) (92.90) (105.23) (1.52k) (415.43)
’20 (104.98) (170.07) (147.13) (275.39) (697.57)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 255,000.00 41,250.00 4,687.50 667.50 348.75 371.25 108.75 24.25 23.25 4.00

Analyst estimates 2026–2028

Powerpack
High 1,012,500.00 399,375.00 101,250.00 9,187.50 1,335.00 2,032.50 810.00 180.00 66.75 57.75
People
People Employees 65 37 37 12 12 14 17 20 21 28
Revenue/emp, $m 0.07 0.07 0.08 0.58 0.03 0.00 0.01 0.25 0.28 0.19
Income, $m
Income, $m Revenue 5 3 3 7 0 — 0 5 6 5
Gross margin, % 41.69 5.43 100.00 100.00 100.00 0.00 100.00 100.00 100.00 100.00
EBT (22) (23) (9) (3) (8) (13) (20) (13) (13) (22)
EBT margin, % (473.50) (843.66) (297.62) (46.91) (2,719.80) 0.00 (9,051.34) (271.04) (222.84) (429.43)
Net income (22) (23) (13) (11) (8) (13) (20) (13) (13) (22)
Depreciation 2 3 3 1 1 1 1 1 1 0
Per share, $
Per share, $ Revenue 0.27 13,445.00 5,966.00 1,891.35 25.68 0.00 3.20 39.12 21.93 1.68
Earnings (1.27) (131,259.60) (488,886.00) (46,472.28) (697.57) (415.43) (289.64) (106.00) (48.75) (7.25)
Cash flow (1.13) (90,640.00) (23,950.00) (1,596.22) (714.75) (318.27) (185.31) (102.32) (39.74) (6.68)
Capex 0.00 (6,915.00) (266.00) (18.11) (7.88) (2.54) (7.27) (1.27) (2.60) (0.01)
Free cash flow (1.13) (97,555.00) (24,216.00) (1,614.32) (722.63) (320.80) (192.59) (103.59) (42.34) (6.69)
Book value 0.64 65,000.00 10,450.00 313.51 256.86 335.48 92.07 (10.73) (33.69) 1.28
Shares, m 17 0 0 0 0 0 0 0 0 3
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 — 0.00 0.00 0.00 0.00
P/S 1,114,110.82 4.04 0.91 0.48 1.43 — 15.44 1.18 1.31 7.61
P/B 472,173.68 0.84 0.52 2.87 2.95 — 1.26 0.00 0.00 9.93
EV/Sales 1,114,111.84 8.20 6.50 (0.37) 1.19 — (8.71) 1.02 1.91 6.80
EV/FCF (266,261.41) (1.13) (1.46) 0.36 (0.77) — 0.34 (0.39) (0.99) (1.66)
Cash, $m
Cash, $m Operating cash flow (20) (18) (12) (6) (8) (10) (13) (13) (11) (21)
Capex 0 (1) 0 0 0 0 (1) 0 (1) 0
Free cash flow (19) (20) (12) (6) (9) (10) (13) (13) (11) (21)
Balance, $m
Balance, $m Working capital 6 (4) (8) 5 1 14 10 (1) (10) 3
Total debt 18 14 14 12 7 7 5 4 3 1
Net debt 5 3 9 (6) (1) (12) (13) (5) 0 (12)
Shareholders’ equity 11 13 5 1 3 11 6 (1) (9) 4
Returns, %
Returns, % ROA (60.98) (80.52) (54.39) (48.46) (46.65) (78.62) (88.44) (75.54) (144.03) (195.02)
ROIC (78.38) (78.83) (38.77) 0.00 (386.95) 0.00 0.00 0.00 0.00 0.00
ROE (190.12) (222.32) (165.94) (358.37) (393.27) (193.25) (234.65) (522.50) 252.07 903.94
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Cerenome, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
DARE Dare Bioscience, Inc. $14.6M — (loss-making) — (loss-making) +984.43% (above 0%: growing) n/m −30.23% (below 0%: shrinking) (70.56%) (1,582.93%) Compare
ADAPY Adaptimmune Therapeutics PLC $14.6M — (loss-making) — (loss-making) −89.33% (below 0%: shrinking) n/m −174.72% (below 0%: shrinking) 81.71% (221.45%) Compare
CNSY Cerenome, Inc. $14.3M — (loss-making) — (loss-making) −70.43% (below 0%: shrinking) n/m −31.46% (below 0%: shrinking) 100.00% (2,203.65%)
TVRD Tvardi Therapeutics, Inc. $14.3M — (loss-making) — (loss-making) +20.33% (above 0%: growing) n/m −57.26% (below 0%: shrinking) 100.00% 0.00% Compare
CLVSQ Clovis Oncology, Inc. $14.2M — (loss-making) — (loss-making) −19.13% (below 0%: shrinking) n/m +11.83% (above 0%: growing) 71.93% (144.26%) Compare
BCDA BioCardia, Inc. $14.2M — (loss-making) — (loss-making) −93.02% (below 0%: shrinking) n/m −5.15% (below 0%: shrinking) 100.00% 0.00% Compare
RVLP RVL Pharmaceuticals PLC $14.1M — (loss-making) — (loss-making) −2.25% (below 0%: shrinking) n/m −734.24% (below 0%: shrinking) 76.43% (266.66%) Compare
LPCN Lipocine Inc. $13.9M — (loss-making) — (loss-making) −69.48% (below 0%: shrinking) n/m −60.56% (below 0%: shrinking) 100.00% (1,495.11%) Compare
KTTA Pasithea Therapeutics Corp. $13.7M — (loss-making) — (loss-making) +1,494.04% (above 0%: growing) n/m −21.68% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $14.2M — — −10.69% — −43.74% 79.07% (182.86%)

All 614 Biotechnology stocks →

Cerenome, Inc. (CNSY) key facts

  • Concern: Cerenome, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5.2 million, down 10.5% from fiscal 2024.
  • Cerenome, Inc. (CNSY) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, CNSY traded at $1.70, a market capitalization of $14.3 million.
  • Return on equity was 903.9% and debt-to-equity 0.00.
  • Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −44.87 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Cerenome, Inc. (CNSY) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/CNSY · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com